Letter to the Editor: Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment

Documenti analoghi

• Letter: Concerns Regarding the Paradoxical Renal Outcomes in Patients Switching From Entecavir to Tenofovir Alafenamide in the Study by Ogawa et al.
  di: Jingru Ge, et al.
  Pubblicazione: (2026)
• Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B
  di: Cheng‐Hao Tseng, et al.
  Pubblicazione: (2025)
• Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB
  di: Seong Hee Kang, et al.
  Pubblicazione: (2026)
• Letter to: Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B
  di: Yong Wang, et al.
  Pubblicazione: (2025)
• Letter to the Editor Regarding “Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C”
  di: Tiancheng Gong
  Pubblicazione: (2025)